Biological predictors of third-line treatment outcomes in patients with advanced non-small cell lung cancer.

被引：0
|
作者：
Vassias, Antonios
Vassos, Dimitrios
Grapsa, Dimitra
Bakakos, Petros
Rovina, Nikoletta
Syrigos, Konstantinos N.
机构：
[1] Natl & Kapodistrian Univ Athens, Med Sch, Dept Med 3, Oncol Unit, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Med Sch, Resp Med Dept 1, Athens, Greece
[3] Athens Univ, Sch Med, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21597
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    [J]. JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [2] Phase II study of tarceva as third-line treatment in advanced non-small cell lung cancer
    de Castro, Javier
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Paz-Ares, Luis
    Gonzalez-Larriba, Jose Luis
    Insa, Amelia
    Domine, Manuel
    Sanchez, Rocio
    Massuti, Bartomeu
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [3] Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer
    Tatli, Ali Murat
    Arslan, Deniz
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Gunduz, Seyda Gulenay
    Coskun, Hasan Senol
    Ozdogan, Mustafa
    Savas, Burhan
    Bozcuk, Hakan Sat
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 805 - 809
  • [4] Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Beninato, T.
    Manglaviti, S.
    Zattarin, E.
    Apollonio, G.
    Galli, E.
    Bini, M.
    Sposetti, C.
    Massa, G.
    Bottiglieri, A.
    Ganzinelli, M.
    Proto, C.
    Ferrara, R.
    Prelaj, A.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    De Braud, F. G. M.
    Garassino, M. C.
    Lo Russo, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1078 - S1078
  • [5] Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer
    Park, Seh Jung
    Choi, In Keun
    Seo, Hee Yun
    Sung, Hwa Jung
    Park, Kyong Hwa
    Oh, Sang Cheul
    Seo, Jae Hong
    Shin, Sang Won
    Kim, Yeul Hong
    Kim, Jun Suk
    [J]. ONCOLOGY LETTERS, 2010, 1 (01) : 51 - 55
  • [6] Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    Corral Jaime, Jesus
    Gonzalez de la Pena, Miriam
    Alonso, Miriam
    Sanchez Gastaldo, Amparo
    Dolores Mediano, Maria
    Amerigo, Marta
    Enrique Robles, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: Efficacy and tolerability
    Camps, C
    Caballero, C
    Blasco, A
    Safont, MJ
    Berrocal, A
    Garde, J
    Juarez, A
    Sirera, R
    Bremnes, RM
    [J]. ANTICANCER RESEARCH, 2005, 25 (6C) : 4611 - 4614
  • [8] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [9] Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
    Sun, Jong-Mu
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Yu Jung
    Yoon, Ho Il
    Lee, Jae-Ho
    Lee, Choon-Taek
    Lee, Jong Seok
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (01) : 27 - 32
  • [10] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    [J]. ONCOLOGIST, 2008, 13 : 14 - 20
12345